Preclinical and Phase 1/2 Data of the CHK1 Inhibitor BBI-355 in Development for Esophageal and Gastric Cancers (EGC) with EGFR or FGFR2 Amplifications.
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined